MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Spasticity: Treatment"

  • 2018 International Congress

    Use of the Non-Medication Complex in the Treatment of the Spasticity

    O. Tondiy (Kharkiv, Ukraine)

    Objective: The effect of the non-medication (physiotherapy) complex (ultratonetherapy, low-frequent variable magnetic field and balneothrapy) on the patients having spasticity was investigated. Background: 110 patients…
  • 2017 International Congress

    The Adult Spasticity International Registry (ASPIRE) Study: 1 Year Results

    G. Francisco, D. Bandari, G. Bavikatte, W. Jost, A. Manack Adams, J. Largent, A. Esquenazi (Houston, TX, USA)

    Objective: To evaluate the 1-year interim onabotulinumtoxinA safety, effectiveness, and exploratory treatment utilization data from the ASPIRE study. Background: OnabotulinumtoxinA treatment for patients with spasticity…
  • 2017 International Congress

    The Adult Spasticity International Registry (ASPIRE) Study: Treatment Utilization Patterns in Patients Treated for Both Upper and Lower Limb Spasticity

    G. Francisco, D. Bandari, G. Bavikatte, W. Jost, A. Manack Adams, J. Largent, A. Esquenazi (Houston, TX, USA)

    Objective: To examine the treatment patterns of onabotulinumtoxinA utilization in patients treated for upper and lower limb spasticity, in combination, from the ASPIRE study (1…
  • 2017 International Congress

    Efficacy of IncobotulinumtoxinA in Treatment of Lower Limb Spasticity in Adults

    D. Simpson, J. Wissel, D. Bensmail, A. Scheschonka, B. Flatau-Baqué, O. Simon (New York, NY, USA)

    Objective: To evaluate the effectiveness of incobotulinumtoxinA for treating key clinical patterns of lower limb (LL) spasticity (eg, pes equinovarus) using a post-hoc analysis. Background:…
  • 2017 International Congress

    Efficacy of IncobotulinumtoxinA for the Treatment Of Shoulder Spasticity

    D. Simpson, J. Wissel, D. Bensmail, A. Scheschonka, B. Flatau-Baqué, O. Simon (New York, NY, USA)

    Objective: To evaluate efficacy of botulinum toxin for shoulder spasticity using a post-hoc analysis. Background: Botulinum toxin has been shown to be effective for treating…
  • 2017 International Congress

    Time to retreatment with botulinum toxin A in upper limb spasticity management: initial data from the Upper Limb International Spasticity (ULIS)-III study

    L. Turner-Stokes, S. Ashford, J. Jacinto, K. Fheodoroff, G. Suarez, P. Maisonobe (London, United Kingdom)

    Objective: The ongoing ULIS-III study aims to describe real-life clinical practice and assess patient‑centered goal attainment with integrated upper limb spasticity (ULS) management that includes…
  • 2016 International Congress

    Use of the physiotherapy in the treatment of initial stages of Parkinson’s disease

    O.L. Tondiy (Kharkiv, Ukraine)

    Objective: Stage of Parkinson's disease was determined by the Hoehn&Yahr Scale. Background: The effect of the low-frequent variable magnetic field, the ultratonetherapy and balneotherapy on…
  • 2016 International Congress

    An innovative international educational network to improve physicians’ current management practices of patients with cervical dystonia and spasticity

    C. Colosimo, K. Bhatia, R. Bhidayasiri, T.M. Chung, L.J. Jacinto, T. Landreau, K. Fheodoroff (Terni, Italy)

    Objective: The Ixcellence Network® aims to improve patient care in the fields of cervical dystonia (CD) and spasticity through the development of a high level…
  • 2016 International Congress

    A phase 3, placebo-controlled study with an open-label extension: Sustained incobotulinumtoxinA efficacy in upper-limb post-stroke spasticity over 48 weeks

    P. Kanovský, A. Brashear, E.P. Elovic, M.C. Munin, A. Hanschmann, R. Hiersemenzel, C. Marciniak (Olomouc, Czech Republic)

    Objective: To assess the efficacy and safety of incobotulinumtoxinA for upper-limb post-stroke spasticity. Background: Botulinum toxin injections are a recommended therapy for limb spasticity. We…
  • 2016 International Congress

    Safety and efficacy of escalating doses of incobotulinumtoxinA (400-800U): Increasing improvements in disability due to multifocal upper- and lower-limb spasticity

    J. Wissel, D. Bensmail, B. Rubin, A. Scheschonka, O. Simon, D.M. Simpson (Berlin, Germany)

    Objective: To assess the safety and efficacy of escalating incobotulinumtoxinA doses (400-800U) in patients with spasticity. Background: Botulinum toxin treatment at higher doses than currently…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley